Noriko Fujiwara

Noriko Fujiwara

Auto-generated profile, based on publicly available information

Noriko Fujiwara

Department of Palliative Medicine and Advanced Clinical Oncology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
JSJalid Sehouli
Jalid Sehouli
Jolijn D. BoerJolijn D. Boer
Jolijn D. Boer
ABAlison H Brand
Alison H Brand
AOAmit Oza
Amit Oza
JOJennifer O’dOnnell
Jennifer O’dOnnell
MBMichael A Bookman
Michael A Bookman
Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of the real-world population. Ideally, patients enrolled in clinical trials should represent a broader population to enhance external validity and facilitate translation of outcomes across all relevant groups. Specifically, there has been a systematic lack of data for underrepresented groups, with many studies failing to report or differentiate study participants based on sociodemographic domains, such as race and ethnicity. As such, the impact of treatment in these underrepresented groups is poorly understood, and clinical outcomes according to various sociodemographic factors are infrequently assessed. Inclusion of diverse trial participants, with different racial and ethnic background, is essential for the understanding of factors that may impact clinical outcomes. Therefore, we conducted a multi-national meeting of clinical trial groups and industry with the goal of increasing equity, diversity, and inclusion in gynecologic cancer clinical trials and to address barriers to recruitment, participation, and harmonization of data collection and reporting. These Gynecologic Cancer Intergroup (GCIG) statements present recommendations and strategies for the gynecologic cancer research community to improve equity, diversity, and inclusion in gynecologic cancer clinical trials.

5 March 2023 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
NFNoriko Fujiwara
Noriko Fujiwara
NSNaoki Shimada
Naoki Shimada
MNMasanori Nojima
Masanori Nojima
KAKeisuke Ariyoshi
Keisuke Ariyoshi
NSNorie Sawada
Norie Sawada
STShoichiro Tsugane
Shoichiro Tsugane
BackgroundThe place of death and related factor such as diseases, symptoms, family burden, and cost has been examined, but social background and lifestyle were not considered in most studies. Here, we assessed factors that are associated with the place of death using the largest cohort study in Japan.MethodsA total of 17,546 deaths from the cohort study were assessed. The study database was created from the Japan Public Health Center-based Prospective Study (JPHC Study) in which demographic data were collected by Japanese Vital Statistics. Adjusted odds ratios for home death were calculated by logistic regression.ResultsMultivariate analysis adjusted for various factors showed that unmarried status (OR 2.4, 95%CI:2.0-2.9), unemployed male (OR 1.3, 95%CI: 1.1-1.5), and high drinking level (OR 1.3, 95%CI:1.1-1.6) were associated with home death. Regarding the cause of death, cardiovascular disease (OR 3.3, 95%CI:2.9-3.8), cerebrovascular disease (OR 1.9, 95%CI:1.6-2.2) and external factors (OR 4.1, 95%CI:3.5-4.8) were significantly associated with home death, compared with cancer. The risk of death at home was significantly higher in unmarried status stratified by cause of death (OR: cardiovascular 3.2, 95%CI:2.2-4.7 / cerebrovascular 5.0, 95%CI:2.8-8.9 / respiratory 3.4, 95%CI:1.6-7.6/ external 2.3, 95%CI:1.4-3.7), but for cancer, the risk of death at home tended to be higher in married status.ConclusionsThis study indicated that various factors are associated with home death using the largest cohort study in Japan. There is a high possibility of home deaths in people with fewer social connections and in those with diseases leading to sudden death.

23 June 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
KFKeiichi Fujiwara
Keiichi Fujiwara
SCStephen Robert Connor
Stephen Robert Connor
NFNoriko Fujiwara
Noriko Fujiwara
RORaimundo C. Oliveira
Raimundo C. Oliveira
AMAnisa Mburu
Anisa Mburu
MPMichael Loran Pearl
Michael Loran Pearl
At the International Gynecologic Cancer Society (IGCS) Global Meeting in 2023 held in Seoul, South Korea, we held a Presidential Plenary Session focusing on palliative care (https://www.youtube.com/watch?v=TBDIoQ50xgI). We hereby reaffirm the significance of this session, express the Palliative Care Declaration made by the IGCS, and describe our action plan for the future.

1 January 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
DTDavid Tan
David Tan
NFNoriko Fujiwara
Noriko Fujiwara
KFKeiichi Fujiwara
Keiichi Fujiwara
PBPhilip Beale
Philip Beale
HKHak Jae Kim
Hak Jae Kim
O(on behalf of The Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
on behalf of The Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Tan D, et al. J Gynecol Oncol. 2023 Feb;34:e33. https://doi.org/10.3802/jgo.2023.34.e33

13 December 2022 in Journal of Pain & Palliative Care Pharmacotherapy
Verified
Journal Article
Closed access
AWAya Watanabe
Aya Watanabe
NSNaoki Shimada
Naoki Shimada
HIHiroto Ishiki
Hiroto Ishiki
NFNoriko Fujiwara
Noriko Fujiwara
MNMasanori Nojima
Masanori Nojima
ATArinobu Tojo
Arinobu Tojo
Cancer pain is a significant issue in terminally ill cancer patients (TICPs). The fentanyl patch (FP) is used extensively for treating cancer pain, but FP requirements vary between patients. We aimed to identify determinants of FP requirements in TICPs and propose effective pain relief using a FP. In a retrospective chart review, we investigated cancer patients admitted to our hospital from April 2012 to July 2015 and used FP until death. The time course of FP use in TICPs until death was examined. The primary endpoint was the final dose of FP use (FDFP). In total, 79 patients were included the analysis. FDFP was inversely correlated with age (R= −0.262, p = 0.20; Spearman test). FDFP tended to be higher in males than in females and was significantly higher in patients with pancreatic cancer than in patients without pancreatic cancer (p = 0.017; Welch’s test). FP adjustments were more frequent in the last 60 days of life in patients with pancreatic cancer than in patients with other malignancies (P for interaction = 0.002; mixed effect model). In conclusion, younger age, and pancreatic cancer were associated with higher FP requirements in TICPs. TICPs with pancreatic cancer required more frequent FP adjustment near death.

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
DTDavid Tan
David Tan
NFNoriko Fujiwara
Noriko Fujiwara
KFKeiichi Fujiwara
Keiichi Fujiwara
PBPhilip Beale
Philip Beale
HKHak Jae Kim
Hak Jae Kim
O(On behalf of The Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
On behalf of The Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Tan D, et al. J Gynecol Oncol. 2025 Sep;36:e131. https://doi.org/10.3802/jgo.2025.36.e131